Diksmuide N35f: zuidwestelijke omleiding tussen de N369 en de N35. Historisch en archeologisch vooronderzoek

Dit rapport werd ingediend bij het agentschap samen met een aantal afzonderlijke digitale bijlagen. Een aantal van deze bijlagen zijn niet inbegrepen in dit pdf document en zijn niet online beschikbaar. Sommige bijlagen (grondplannen, fotos, spoorbeschrijvingen, enz.) kunnen van belang zijn voor een betere lezing en interpretatie van dit rapport. Indien u deze bijlagen wenst te raadplegen kan u daarvoor contact opnemen met: [email protected]

Plan d'une maison du groupe de Deûle-Escaut à Waardamme (Oostkamp, Flandre occidentale)

A

Flow cytometric detection of intracellular myeloperoxidase in equine polymophonuclear leukocytes

Myeloperoxidase (MPO) is considered to be selectively expressed in germinative cells of granulocytes and monocytes but not lymphocytes. In human diagnostic medicine the intracellular detection of MPO has become a valuable clinical tool for pathologies such as acute myeloid leukemia. Intracellular MPO detection might also be relevant in equine pathological conditions. Therefore, we developed a standardized flow cytometric protocol for the detection of equine intracellular MPO, including the choice of permeabilization technique (Fix and Perm versus Formaldehyde and FACSPerm), of secondary antibody in the indirect approach (Alexa Fluor 488 versus Allophycocyanin (APC) labeled secondary antibody) and of fluorochrome for the primary antibody in the direct labeling alternative approach (DyLight 649 versus Atto633). Titrations of these antibodies and controls for reproducibility were included. The Fix and Perm protocol resulted in the lower background staining and within-horse variation compared to the tests with Formaldehyde and FACSPerm. In the indirect staining technique, the Alexa Fluor 488 labeled antibody was superior to the APC labeled alternative with respect to variability and discrimination potential of the three leukocyte populations. For the direct staining of the primary antibody, the DyLight 649 fluorochrome was the preferred choice being characterized by a stronger fluorescent signal with lower spread and also the ability to discriminate between equine neutrophil, monocyte and lymphocyte populations, in contrast to the Atto633 labeled antibody. Optimal concentrations for all selected antibodies were determined. The good repeatability of the primary antibody titration illustrated the reproducibility of the flow cytometric technique. The defined flow cytometric protocols for indirect and direct intracellular MPO detection will be applied in ongoing research to validate the possible diagnostic properties of MPO in equine infectious versus non-infectious joint disease. Research funded by a Ph.D. grant of the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen

Flow cytometric detection of myeloperoxidase in horse neutrophils: a novel technique in equine diagnostic research.

Myeloperoxidase (MPO) is a protein of interest due to its involvement in equine pathologies. Until now, results in equine diagnostic research were achieved through extracellular MPO detection. However, studying the cellular MPO content in neutrophils has revealed important insights in human diseases. This study aimed to develop a technique for the specific detection of MPO on the single cell level defining a flow cytometric protocol for the detection of both equine surface-bound and cellular MPO. Both indirect and direct labeling techniques are described which include the comparison of two secondary antibodies and two linking-fluorochromes, respectively

Health-related quality of life in patients undergoing laparoscopic versus open hemihepatectomy: a secondary analysis of the ORANGE II PLUS randomised controlled, phase 3, superiority trialResearch in context

Summary: Background: Health-related quality of life (HRQoL) has become a critical factor in determining the benefits of new surgical approaches on patients. The ORANGE II PLUS randomised trial compared laparoscopic (LH) and open (OH) hemihepatectomy in an international multicentre randomised controlled setting, with HRQoL as a secondary outcome. The aim of this study was to perform an in-depth analysis of the HRQoL outcomes. Methods: Between October 2013 and January 2019, 352 patients scheduled for hemihepatectomy, were randomly assigned to either LH or OH in a 1:1-ratio in 16 European centres. HRQoL was assessed using the EORTC-QLQ-C30 and QLQ-LMC21 modules, at baseline, hospital discharge, and at 10-days, 3-, 6-, and 12-months after discharge. Differences in functioning- and five selected symptom scales were compared between LH and OH over the cumulative periods from discharge to 3 months as well as to 12 months using a multivariable adjusted linear mixed regression model. The study was registered at ClinicalTrials.gov (NCT01441856). Findings: The modified intention-to-treat analysis included 332 patients (166 LH and 166 OH), with 40% female in LH and 42% female in OH. 1546 questionnaires (81% of maximum) were obtained. Cumulatively over the period from discharge to 3 months postoperatively, patients in the laparoscopic group reported better physical (difference 4.20 points; 95% CI 1.07–7.34) and social functioning (5.95 points; 95% CI 1.65–10.26), and lower pain (−6.41 points, 95% CI −10.01 to −2.82) and appetite loss (−7.29 points, 95% CI −11.59 to −2.99), compared to the OH group. Similar clinically relevant, but slightly attenuated, differences were reported over the cumulative period from discharge to 12 months after surgery. The largest difference was observed at 10 days after surgery. Interpretation: In this international randomised trial evaluating HRQoL, LH demonstrated better physical and social functioning, and less pain and appetite loss, compared to OH. These findings support the preferential use of the laparoscopic approach for hemihepatectomy in experienced centres. Funding: Maastricht University Medical Centre+, University Hospital RWTH Aachen, Cancer Research UK 12/048, European Association of Endoscopic Surgery, participating centres